Acute profound thrombocytopenia without bleeding complications after re-sdministration of abciximab

Journal of Invasive Cardiology

Volumn 13, Issue 1, 2001, Pages 56-58

  Nguyen, Niem ^a   Salib, Hayman ^a   Mascarenhas, Daniel A N ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Abciximab; Glycoprotein IIb IIIa; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; GLUCOCORTICOID; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ACUTE DISEASE; ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; THROMBOCYTOPENIA; THROMBOLYTIC THERAPY;

EID: 0035219614     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
2. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
3. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
4. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
5. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopcnia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998;32:311-319.
6. Ferrari E, Thiry M, Touati C, et al. Acute profound thrombocytopenia after c7E3 Fab therapy. Circulation 1997;96:3809-3810.
7. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
8. Elmi F, Oza R, Mascarenhas DAN. Acute profound thrombocytopenia without bleeding complications after abciximab administration. J Invas Cardiol 1999;11:313-315.
9. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139:S38-S45.
10. Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med 1992;22:145-152.
11. Aster RH. Heparin-induced thrombocytopenia. N Engl J Med 1995;332:1374-1376.
12. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
13. Mak KH, Kottke-Marchant K, Brooks LM, et al. Potential value of platelet GP IIb/IIIa antagonist for treating heparin-induced thrombocytopenia (HIT) (Abstr). J Am Coll Cardiol 1996;27:316A.
14. Jennings LK, White MM. Expression of ligan-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J 1998;135:S179-S183.